Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6151882 | 1.00 | ELANE (0.35) | ELANETSHRALDH1A1HSD17B10TDP1 | |
| SCHEMBL7020601 | 0.82 | ELANE (0.38) | ELANEALDH1A1 | |
| SCHEMBL6150759 | 0.79 | ELANE (0.31) | ELANE | |
| SCHEMBL3079101 | 0.69 | ELANE (0.52) | ELANETSHRALDH1A1KMT2A | |
| SCHEMBL3075582 | 0.69 | ELANE (0.52) | ELANETSHRALDH1A1KMT2A | |
| SCHEMBL3079099 | 0.69 | ELANE (0.52) | ELANETSHRALDH1A1KMT2A | |
| SCHEMBL3076587 | 0.65 | ELANE (0.51) | ELANEKMT2A | |
| SCHEMBL3076591 | 0.65 | ELANE (0.51) | ELANEKMT2A | |
| SCHEMBL6860240 | 0.62 | ELANE (0.47) | ELANEALDH1A1 | |
| SCHEMBL22924627 | 0.62 | TSHR (0.57) | TSHRALDH1A1HSD17B10TDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1260222-B1 | Pharmaceutical compositions containing new iso-butenyl substituted taxanes | UNIV FLORIDA STATE (US) | 2005-10-26 | — | — | EP | disclosed |
| US-6872842-B2 | Antileukemia and antitumor agents | FLORIDA STATE UNIVERSITY (US) | 2005-03-29 | — | — | US | disclosed |
| US-6794523-B2 | ANTICANCER AGENTS, ANTITUMOR AGENTS; LEUKEMIA | FLORIDA STATE UNIVERSITY | 2004-09-21 | — | — | US | disclosed |
| US-20030065200-A1 | Anticancer agents, antitumor agents; leukemia | FLORIDA STATE UNIVERSITY | 2003-04-03 | — | — | US | disclosed |
| US-20030045531-A1 | Antileukemia and antitumor agents | FLORIDA STATE UNIVERSITY | 2003-03-06 | — | — | US | disclosed |
| EP-1260222-A1 | Butenyl-substituted taxanes and composition | Florida State University (US) | 2002-11-27 | — | — | EP | disclosed |
| US-6395895-B1 | Butenyl substituted β-lactams | FLORIDA STATE UNIVERSITY | 2002-05-28 | — | — | US | disclosed |
| US-6018073-A | Tricyclic taxanes having an alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing them | FLORIDA STATE UNIVERSITY (US) | 2000-01-25 | — | — | US | disclosed |
| US-5739362-A | ANTILEUKEMIA, ANTITUMOR AGENTS | FLORIDA STATE UNIVERSITY (US) | 1998-04-14 | — | — | US | disclosed |
| US-5728850-A | ANTITUMOR AGENTS | FLORIDA STATE UNIVERSITY (US) | 1998-03-17 | — | — | US | disclosed |
| EP-0668762-A4 | BUTENYL-SUBSTITUTED TAXANES AND COMPOSITION. | UNIV FLORIDA STATE (US) | 1995-12-20 | — | — | EP | disclosed |
| EP-0668762-A1 | BUTENYL-SUBSTITUTED TAXANES AND COMPOSITION | FLORIDA STATE UNIVERSITY (US) | 1995-08-30 | — | — | EP | disclosed |
| WO-1994010996-A1 | BUTENYL-SUBSTITUTED TAXANES AND COMPOSITION | FLORIDA STATE UNIVERSITY (US) | 1994-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045531-A1 | Antileukemia and antitumor agents | MCL1, BCL3, BCL2L13 | ELANE 684/4885TSHR 3954/4885ALDH1A1 990/4885 |
| US-20030065200-A1 | Anticancer agents, antitumor agents; leukemia | MCL1, BCL3, TOP2A | ELANE 671/4885TSHR 3453/4885ALDH1A1 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.